EPS: As of FY2025 Q2, the actual value is USD -0.9, missing the estimate of USD -0.6971.<h3>Segment Revenue</h3><ul><li>The company has not generated any product revenue to date and expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances product candidates through all stages of development and clinical trials.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: The net loss for the six months ended June 30, 2025, was $95.8 million, compared to $39.3 million for the same period in 2024, reflecting an increase of $56.5 million.</li><li>Operating Loss: The operating loss for the six months ended June 30, 2025, was $100.4 million, compared to $46.4 million for the same period in 2024, reflecting an increase of $54.0 million.</li><li>Research and Development Expenses: These expenses were $89.0 million for the six months ended June 30, 2025, compared to $38.8 million for the same period in 2024, reflecting an increase of $50.3 million.</li><li>General and Administrative Expenses: These expenses were $11.4 million for the six months ended June 30, 2025, compared to $7.6 million for the same period in 2024, reflecting an increase of $3.8 million.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the six months ended June 30, 2025, net cash used in operating activities was $94.1 million, compared to $37.7 million for the same period in 2024.</li><li>Net Cash Provided by Investing Activities: For the six months ended June 30, 2025, net cash provided by investing activities was $50.7 million, primarily due to maturities of marketable securities.</li><li>Net Cash Provided by Financing Activities: For the six months ended June 30, 2025, net cash provided by financing activities was $81.9 million, primarily due to sales under the ATM Program.</li></ul><h3>Unique Metrics</h3><ul><li>Stock-Based Compensation Expense: The company recorded stock-based compensation expense of $5.6 million for the six months ended June 30, 2025.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to advance its lead product candidate, firmonertinib, as well as ARR-217, through clinical trials, and further invest in its pipeline. It also plans to seek regulatory approval for its product candidates and pursue commercialization if approved.</li><li>Non-Core Business: The company is exploring additional product candidates and anticipates acquiring or in-licensing additional product candidates to expand its pipeline.</li><li>Priority: The company emphasizes the need for additional capital to fund its future operating and capital requirements, with a focus on advancing its clinical trials and expanding its pipeline.</li></ul>

ArriVent Biopharma | 10-Q: FY2025 Q2 EPS Misses Estimate at USD -0.9